U6 promoter-enhanced GlnUAG suppressor tRNA has higher suppression efficacy and can be stably expressed in 293 cells

Journal of Gene Medicine

Volumn 15, Issue 2, 2013, Pages 93-101

  Koukuntla, Ramesh ^a   Ramsey, William J ^b   Young, Won Bin ^b   Link, Charles J ^a,b  

^a IOWA STATE UNIVERSITY   (United States)

^b NEWLINK GENETICS   (United States)

Author keywords

Gene therapy; Nonsense suppressor tRNA; Premature termination codons; U6 promoter

Indexed keywords

CELL PROTEIN; GLUTAMINE; GLUTAMINE AMBER SUPPRESSOR TRANSFER RNA; LENTIVIRUS VECTOR; TRANSFER RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL SPECIFICITY; CELL STRAIN HEK293; CELL TYPE; GENE EXPRESSION; GENE THERAPY; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOP CODON; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ANTICODON; BLOTTING, WESTERN; CLONING, MOLECULAR; CODON, NONSENSE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION; GENES, SUPPRESSOR; GENETIC THERAPY; GENETIC VECTORS; GLUTAMINE; HEK293 CELLS; HUMANS; LENTIVIRUS; PROMOTER REGIONS, GENETIC; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, TRANSFER;

EID: 84874366833     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2696     Document Type: Article

References (51)

1. Strasser BJ. A world in one dimension: Linus Pauling, Francis Crick and the central dogma of molecular biology. Hist Philos Life Sci 2006; 28: 491-512.
2. Cavener DR, Ray SC. Eukaryotic start and stop translation sites. Nucleic Acids Res 1991; 19: 3185-3192.
3. Atkinson J, Martin R. Mutations to nonsense codons in human genetic disease: implications for gene therapy by nonsense suppressor tRNAs. Nucleic Acids Res 1994; 22: 1327-1334.
4. Capecchi MR, Hughes SH, Wahl GM. Yeast super-suppressors are altered tRNAs capable of translating a nonsense codon in vitro. Cell 1975; 6: 269-277.
5. Capecchi MR, Haar RA, Capecchi NE et al. The isolation of a suppressible nonsense mutant in mammalian cells. Cell 1977; 12: 371-381.
6. Temple GF, Dozy AM, Roy KL et al. Construction of a functional human suppressor tRNA gene: an approach to gene therapy for beta-thalassaemia. Nature 1982; 296: 537-540.
7. Panchal RG, Wang S, McDermott J et al. Partial functional correction of xeroderma pigmentosum group A cells by suppressor tRNA. Hum Gene Ther 1999; 10: 2209-2219.
8. Kuzmiak HA, Maquat LE. Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges. Trends Mol Med 2006; 12: 306-316.
9. McCaughan KK, Brown CM, Dalphin ME et al. Translational termination efficiency in mammals is influenced by the base following the stop codon. Proc Natl Acad Sci USA 1995; 92: 5431-5435.
10. Gieg R, Sissler M, Florentz C. Universal rules and idiosyncratic features in tRNA identity. Nucleic Acids Res 1998; 26: 5017-5035.
11. Buvoli M, Buvoli A, Leinwand LA. Suppression of nonsense mutations in cell culture and mice by multimerized suppressor tRNA genes. Mol Cell Biol 2000; 20: 3116-3124.
12. Janzen DM, Geballe AP. The effect of eukaryotic release factor depletion on translation termination in human cell lines. Nucleic Acids Res 2004; 32: 4491-4502.
13. Ganoza MC, Tomkins JK. Polypeptide chain termination in vitro: competition for nonsense codons between a purified release factor and suppressor tRNA. Biochem Biophys Res Commun 1970; 40: 1455-1463.
14. Li L, Linning RM, Kondo K et al. Differential expression of individual suppressor tRNA(Trp) gene gene family members in vitro and in vivo in the nematode Caenorhabditis elegans. Mol Cell Biol 1998; 18: 703-709.
15. Srinivasan L, Gopinathan KP. Differential expression of individual gene copies from within a tRNA multigene family in the mulberry silkworm Bombyx mori. Insect Molecular Biol 2001; 10: 523-530.
16. Hudziak RM, Laski FA, RajBhandary UL et al. Establishment of mammalian cell lines containing multiple nonsense mutations and functional suppressor tRNA genes. Cell 1982; 31: 137-146.
17. Laski FA, Ganguly S, Sharp PA et al. Construction, stable transformation, and function of an amber suppressor tRNA gene in Drosophila melanogaster. Proc Natl Acad Sci USA 1989; 86: 6696-6698.
18. Drabkin HJ, Park HJ, RajBhandary UL. Amber suppression in mammalian cells dependent upon expression of an Escherichia coli aminoacyl-tRNA synthetase gene. Mol Cell Biol 1996; 16: 907-913.
19. K'hrer C, Sullivan EL, RajBhandary UL. Complete set of orthogonal 21st aminoacyl-tRNA synthetase-amber, ochre and opal suppressor tRNA pairs: concomitant suppression of three different termination codons in an mRNA in mammalian cells. Nucleic Acids Res 2004; 32: 6200-6211.
20. Lai D, Weng S, Wang C et al. Small antisense RNA to cyclin D1 generated by pre-tRNA splicing inhibits growth of human hepatoma cells. FEBS Lett 2004; 576: 481-486.
21. Roy KL, Cooke H, Buckland R. Nucleotide sequence of a segment of human DNA containing the three tRNA genes. Nucleic Acids Res 1982; 10: 7313-7322.
22. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 1975; 250: 4007-4021.
23. Choisne N, Martin-Canadell A, Small I. Transactivation of a target gene using a suppressor tRNA in transgenic tobacco plants. Plant J 1997; 11: 597-604.
24. Liberek K, Lewandowska A, Zietkiewicz S. Chaperones in control of protein disaggregation. EMBO J 2008; 27: 328-335.
25. Li Z, Srivastava P. Heat-shock proteins. Curr Protoc Immunol 2004; Appendix 1: Appendix 1T.
26. Agashe VR, Hartl FU. Roles of molecular chaperones in cytoplasmic protein folding. Semin Cell Dev Biol 2000; 11: 15-25.
27. Park HJ, RajBhandary UL. Tetracycline-regulated suppression of amber codons in mammalian cells. Mol Cell Biol 1998; 18: 4418-4425.
28. Kondo K, Hodgkin J, Waterston RH. Differential expression of five tRNA(UAGTrp) amber suppressors in Caenorhabditis elegans. Mol Cell Biol 1988; 8: 3627-3635.
29. Dittmar KA, Goodenbour JM, Pan T. Tissue-specific differences in human transfer RNA expression. PLoS Genet 2006; 2: e221.
30. Cooper DN. Human gene mutations affecting RNA processing and translation. Ann Med 1993; 25: 11-17.
31. Conne B, Stutz A, Vassalli JD. The 3′ untranslated region of messenger RNA: a molecular 'hotspot' for pathology? Nat Med 2000; 6: 637-641.
32. Tanguay RL, Gallie DR. Translational efficiency is regulated by the length of the 3′ untranslated region. Mol Cell Biol 1996; 16: 146-156.
33. Bienz M, Kubli E, Kohli J et al. Usage of the three termination codons in a single eukaryotic cell, the Xenopus laevis oocyte. Nucleic Acids Res 1981; 9: 3835-3850.
34. Hamed SA. Drug evaluation: PTC-124 - a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. IDrugs 2006; 9: 783-789.
35. James PD, Raut S, Rivard GE et al. Aminoglycoside suppression of nonsense mutations in severe haemophilia. Blood 2005; 106: 3043-3048.
36. Lai C-H, Chun HH, Nahas SA et al. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci USA 2004; 101: 15676-15681.
37. Wagner KR, Hamed S, Hadley DW et al. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001; 49: 706-711.
38. Wilschanski M, Yahav Y, Yaacov Y et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. New Engl J Med 2003; 349: 1433-1441.
39. Palmer E, Wilhelm JM, Sherman F. Phenotypic suppression of nonsense mutants in yeast by aminoglycoside antibiotics. Nature 1979; 277: 148-150.
40. Burke JF, Mogg AE. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res 1985; 13: 6265-6272.
41. Diop D, Chauvin CL, Jean-Jean O. Aminoglycosides and other factors promoting stop codon readthrough in human cells. C R Biol 2007; 330: 71-79.
42. Bidou L, Hatin I, Perez N et al. Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment. Gene Ther 2004; 11: 619-627.
43. Clancy JP, Rowe SM, Bebok Z et al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Resp Cell Mol Biol 2007; 37: 57-66.
44. Linde L, Boelz S, Nissim-Rafinia M et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 2007; 117: 683-692.
45. Gozalbo D, Hohmann S. Nonsense suppressors partially revert the decrease of the mRNA level of a nonsense mutant allele in yeast. Curr Genet 1990; 17: 77-79.
46. Warady BA, Reed L, Murphy G et al. Aminoglycoside ototoxicity in pediatric patients receiving long-term peritoneal dialysis. Pediatr Nephrol 1993; 7: 178-181.
47. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002; 6: 622-627.
48. Wang L, Xie J, Schultz PG. Expanding the genetic code. Annu Rev Biophys Biomol Struct 2006; 35: 225-249.
49. Wang L, Schultz PG. A general approach for the generation of orthogonal tRNAs. Chem Biol 2001; 8: 883-890.
50. Ryu Y, Schultz PG. Efficient incorporation of unnatural amino acids into proteins in Escherichia coli. Nat Methods 2006; 3: 263-265.
51. Rodriguez EA, Lester HA, Dougherty DA. In vivo incorporation of multiple unnatural amino acids through nonsense and frameshift suppression. Proc Natl Acad Sci USA 2006; 103: 8650-8655.